Continuous ultrafiltration for congestive heart failure: the CUORE trial

J Card Fail. 2014 May;20(5):378.e1-9.

Abstract

Background: There are limited data comparing ultrafiltration with standard medical therapy as first-line treatment in patients with severe congestive heart failure (HF). We compared ultrafiltration and conventional therapy in patients hospitalized for HF and overt fluid overload.Methods and Results: Fifty-six patients with congestive HF were randomized to receive standard medical therapy (control group; n = 29) or ultrafiltration (ultrafiltration group; = 27). The primary endpoint of the study was rehospitalizations for congestive HF during a 1-year follow-up. Despite similar body weight reduction at hospital discharge in the 2 groups (7.5 ± 4.5 and 7.9 ± 5.0 kg, respectively;P = .75), a lower incidence of rehospitalizations for HF was observed in the ultrafiltration-treated patients during the following year (hazard ratio 0.14, 95% confidence interval 0.04-0.48; P = .002).Ultrafiltration-induced benefit was associated with a more stable renal function, unchanged furosemide dose, and lower B-type natriuretic peptide levels. At 1 year, 7 deaths (30%) occurred in the ultrafiltration group and 11 (44%) in the control group (P = .33).Conclusions: In HF patients with severe fluid overload, first-line treatment with ultrafiltration is associated with a prolonged clinical stabilization and a greater freedom from rehospitalization for congestive HF.

Publication types

  • Corrected and Republished Article
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Follow-Up Studies
  • Heart Failure / diagnosis*
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Hemofiltration / methods*
  • Humans
  • Middle Aged
  • Patient Readmission / trends*
  • Prospective Studies
  • Ultrafiltration / methods